Drug Trial Radar · NCT05368103
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Apr 27, 2022
Primary completion
Aug 7, 2023
Study completion Jan 26, 2024
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- May 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at Screening and Day 1.
Conditions
- Alopecia Areata
Interventions
DaxdilimabBiological
Daxdilimab will be administered subcutaneously as two injections for each dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in SALT Score at Week 24Time frame: Baseline to Week 24
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Burke Pharmaceutical Research
Hot Springs, Arkansas
First OC Dermatology Research, Inc.
Fountain Valley, California
ForCare Clinical Research
Tampa, Florida
DS Research
Louisville, Kentucky
Progressive Clinical Research, P.A.
San Antonio, Texas
Dermatology Specialists of Spokane
Spokane, Washington
Centre de Recherche Saint-Louis (Quebec)
Québec, Canada
Enverus Medical Research
Surrey, British Columbia, Canada
Dr Dusan Sajic Medicine Professional Corporation
Guelph, Ontario, Canada
Lynderm Research Inc.
Markham, Ontario, Canada
The Centre for Clinical Trials
Oakville, Ontario, Canada
SKiN Centre for Dermatology
Peterborough, Ontario, Canada
Innovaderm Research
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.